drugset / Trial / NCT01753570

Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)

NCT01753570

RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy and safety of MP-424 with IFN beta and RBV in patients with genotype 1/2 hepatitis C, who are treatment-naïve or have received its treatment before.

Timeline

Start
2012-12
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Interferon-beta Protein / enzyme biologic 6e+08 iu
Subject RBV Unknown 600 mg
Subject RBV Unknown 1000 mg
Subject Telaprevir Small molecule 750 mg